

FO RJL83

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.
 Serial No. : Unassigned
 Filed : Unassigned
 For : Gene Therapy by Administration of
 Genetically Engineered CD34⁺ Cells
 Obtained from Cord Blood
 Group : Unassigned
 Examiner : Unassigned

Honorable Commissioner of
 Patent and Trademarks
 Washington, D.C. 20231

"Express Mail" Mail Label number: EF116368848U
 Date Of Deposit: April 8, 1994

I hereby certify that this paper or fee is being
 deposited with the United States Postal Service "Express
 Mail Post Office to Addressee" service under 37 CFR
 1.110 on the date indicated above and is addressed to
 the Commissioner of Patents and Trademarks, Washington, D.C.

Colleen Maroney
 (Typed or Printed Name of Person Mailing Paper or Fee)
 Colleen Maroney
 (Signature of Person Mailing Paper or Fee)

SIR:

Enclosed please find the following:

1. Application (4 independent claims, 26 total);
2. Statement Under 37CFR1.821(f);
3. Information Disclosure Statement with references;
4. Computer disc;
5. Check on the amount of \$916.00; and
6. Date Stamped Receipt Card.

If any additional fees are incurred, please charge Deposit
 Account No. 03-0678.

Respectfully submitted

Raymond J. Lillie
 Raymond J. Lillie
 Reg. No. 31,778

F0 RJL79



#984
02-14-95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.
Serial No. : Unassigned
Filed : Unassigned
For : Gene Therapy by Administration of
Genetically Engineered CD34⁺ Cells
Obtained from Cord Blood
Group : Unassigned
Examiner : Unassigned

Honorable Commissioner of
Patent and Trademarks
Washington, D.C. 20231


SIR:

In keeping with Applicants' duty under 37CFR1.56 to disclose information material to the patentability of the above-identified application, the following references, copies of which are enclosed, are hereby made of record.

1. U.S. Patent No.: 5,192,553, Boyse, et al., March 9, 1993;
2. Miller, et al., Biotechniques, Vol. 7, No.9, pgs 980-990 (1989).;
3. Hock, et al., Blood, Vol. 74, No. 2, pgs. 876-881 (August 1, 1989).;
4. Moritz, et al., J. Exp. Med., Vol. 178, pgs. 529-536 (August 1993).;

The above references also are listed on the attached Form PTO-1449. It is respectfully requested that the Examiner consider these references.

Respectfully submitted,


Raymond J. Lillie
Reg. No. 31,778

F0 RJL78



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.
Serial No. : Unassigned
Filed : Unassigned
For : Gene Therapy by Administration of
Genetically Engineered CD34⁺ Cells
Obtained from Cord Blood
Group : Unassigned
Examiner : Unassigned

Honorable Commissioner of
Patent and Trademarks
Washington, D.C. 20231
BOX SEQUENCE

STATEMENT UNDER 37 CFR1.821(f)

SIR:

Pursuant to 37 CFR1.821(f), please be advised that the paper
and computer readable copies of the sequence listing are the same.

Respectfully submitted,

A handwritten signature in cursive script, reading "Raymond J. Lilfie".

Raymond J. Lilfie
Reg. No. 31,778